SAN DIEGO, April 20, 2021 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update
Conference Call for the first quarter 2021 on Monday, May 10 at 4:30
p.m. ET / 1:30 p.m. PT. Dr.
Helen Torley, president and chief
executive officer, will lead the call. On the same date, Halozyme
will release financial results for the first quarter ended
March 31, 2021 following the close of
trading.
To register for this conference call, please use this link:
http://www.directeventreg.com/registration/event/1584694. After
registering, you will receive an email confirmation that includes
dial in details and unique conference call codes for entry.
Registration is open through the live call. However, to ensure you
are connected for the full call, we suggest registering a day in
advance or at minimum 10 minutes before the start of the call.
The call will be webcast live through the "Investors" section of
Halozyme's corporate website and a recording will be made available
following the close of the call. To access the webcast and
additional documents related to the call, please visit the
Investors page of www.halozyme.com approximately 15 minutes prior
to the call to register, download and install any necessary audio
software. A telephone replay will be available for two weeks after
the call by dialing (800) 585-8367 (domestic callers) or (416)
621-4642 (international callers) using replay ID number
1584694.
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive
solutions to significantly improve patient experiences and outcomes
for emerging and established therapies. Halozyme advises and
supports its biopharmaceutical partners in key aspects of new drug
development with the goal of improving patients' lives while
helping its partners achieve global commercial success. As the
innovators of the ENHANZE® technology, which can reduce
hours-long treatments to a matter of minutes, Halozyme's
commercially-validated solution has positively impacted more than
400,000 patient lives via five commercialized products across more
than 100 global markets. Halozyme and its world-class partners are
currently advancing multiple therapeutic programs intended to
deliver innovative therapies, with the potential to improve the
lives of patients around the globe. Halozyme's proprietary enzyme
rHuPH20 forms the basis of the ENHANZE® technology and
is used to facilitate the delivery of injected drugs and fluids,
potentially reducing the treatment burden of other drugs to
patients. Halozyme has licensed its ENHANZE® technology
to leading pharmaceutical and biotechnology companies including
Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers
Squibb, Alexion, argenx and Horizon Therapeutics. Halozyme derives
revenues from these collaborations in the form of milestones and
royalties as the Company's partners make progress developing and
commercializing their products being developed with
ENHANZE®. Halozyme is headquartered in San Diego. For more information visit
www.halozyme.com.
Contact:
Al
Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-to-host-first-quarter-2021-financial-results-webcast-and-conference-call-301273073.html
SOURCE Halozyme Therapeutics, Inc.